Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT03684642 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03684642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03684642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
September 26, 2018
Completion date
November 17, 2020
Enrollment
908 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus